Integrated outsourcing transforms and increases R&D productivity


  • Henry Levy



Pharmaceutical companies are actively exploring new sourcing strategies to address the continuing decline in R&D productivity. Fragmented outsourcing has not sufficiently solved the problem, so leaders are moving toward an integrated sourcing model that blends control of the development pipeline with the economies of scalable outsourcing. While many pharmaceutical companies recognize the potential value of this approach, few are prepared to fully exploit it. Accenture has identified four criteria to help pharmaceutical companies successfully increase R&D productivity through integrated outsourcing. Making the necessary changes will not be easy, and individual companies will have to determine the appropriate roadmap they each need to use.   

Author Biography

Henry Levy

is managing director of Accenture Life Sciences’ Research and Development group. He has 20 years of experience with Accenture, previously leading the organization’s life sciences research and development business in Europe, Africa, the Middle East and Latin America. In his current role, Levy specializes in consulting and business transformation for biotechnology companies, with a focus on developing and implementing advanced clinical and regulatory compliance strategies.





From the Boardroom